The history of Viagra presents a intricate picture for investors. While the initial introduction generated substantial returns, the end of its intellectual property protection opened the floodgates to off-brand alternatives, dramatically reducing sales. This poses a particular risk for pharmaceutical companies relying on related blockbuster medicat

The legacy of Viagra, and its developer copyright, presents a intriguing case study for investors. Originally a blockbuster drug, yielding billions in revenue , its patent expiration created a wave of knock-off medications, significantly diminishing its dominance. While certain businesses may try to capitalize on similar conditions , the present la